Loading...
XNAS
TELO
Market cap34mUSD
Jul 11, Last price  
1.16USD
1D
-0.85%
1Q
-56.88%
IPO
-81.44%
Name

Telomir Pharmaceuticals Inc

Chart & Performance

D1W1MN
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
Rev. gr., 5y
%
Revenues
0k
Net income
-17m
L+26.48%
-138,131-854,147-13,071,864-16,532,716
CFO
-5m
L+31.37%
-119,396-468,661-3,859,796-5,070,428

Profile

Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. It develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy recovery by interrupting and preventing the interleukin-17 induced inflammatory pathways. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. on October 10, 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.
IPO date
Feb 09, 2024
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFY
2024‑122023‑122022‑122021‑12
Income
Revenues
Cost of revenue
11,872
6,117
854
Unusual Expense (Income)
NOPBT
(11,872)
(6,117)
(854)
NOPBT Margin
Operating Taxes
(854)
Tax Rate
NOPAT
(11,872)
(6,117)
(3)
Net income
(16,533)
26.48%
(13,072)
1,430.40%
(854)
518.36%
Dividends
Dividend yield
Proceeds from repurchase of equity
6,833
1,000
BB yield
-5.61%
Debt
Debt current
101
582
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
(1,266)
100
580
Cash flow
Cash from operating activities
(5,070)
(3,860)
(469)
CAPEX
(4)
Cash from investing activities
Cash from financing activities
6,335
3,860
470
FCF
(12,671)
(5,673)
337
Balance
Cash
1,266
1
1
Long term investments
Excess cash
1,266
1
1
Stockholders' equity
(30,597)
(14,064)
(992)
Invested Capital
31,240
17,603
637
ROIC
ROCE
240.27%
EV
Common stock shares outstanding
29,539
29,610
29,610
Price
4.12
 
Market cap
121,702
 
EV
120,435
EBITDA
(7,533)
(6,117)
(854)
EV/EBITDA
Interest
4,339
1,643
Interest/NOPBT